Holen Sie sich die Stockscreener-App
0.2242
12.10%
0.0242
Handel nachbörslich:
.22
-0.0042
-1.87%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CTXR?
Forum
Prognose
Aktiensplit
Citius Pharmaceuticals Inc Aktie (CTXR) Neueste Nachrichten
Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering - cnhinews.com
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering - The Malaysian Reserve
Citius Pharmaceuticals Raises $3M in Direct Offering at $0.25 Per Share | CTXR Stock News - StockTitan
What is HC Wainwright’s Estimate for CTXR FY2024 Earnings? - Defense World
Citius Pharmaceuticals stock hits 52-week low at $0.31 - Investing.com
Citius Pharmaceuticals stock hits 52-week low at $0.31 By Investing.com - Investing.com UK
Equities Analysts Set Expectations for CTXR FY2024 Earnings - MarketBeat
What is HC Wainwright’s Forecast for CTXR Q1 Earnings? - Defense World
Citius Pharmaceuticals granted extension to regain Nasdaq compliance - Investing.com
Citius Pharmaceuticals granted extension to regain Nasdaq compliance By Investing.com - Investing.com Australia
Q1 Earnings Forecast for CTXR Issued By HC Wainwright - MarketBeat
Citius Pharmaceuticals (NASDAQ:CTXR) Receives Buy Rating from HC Wainwright - MarketBeat
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors - The Malaysian Reserve
Citius' LYMPHIR Shows Potential To Boost Pembrolizumab Efficacy - Contract Pharma
Citius Pharmaceuticals stock hits 52-week low at $0.32 - Investing.com India
Citius Pharmaceuticals stock hits 52-week low at $0.32 By Investing.com - Investing.com UK
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR): Is Breakeven Near? - Simply Wall St
Citius Pharmaceuticals stock hits 52-week low at $0.34 By Investing.com - Investing.com Australia
Citius Pharmaceuticals stock hits 52-week low at $0.34 - Investing.com India
CTXR (Citius Pharmaceuticals) Cyclically Adjusted Revenue p - GuruFocus.com
Investing in Citius Pharmaceuticals Inc (CTXR) might be a great opportunity, but the stock is a bit undervalued - US Post News
Citius Pharmaceuticals Inc (CTXR) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
Closing Bell Recap: Citius Pharmaceuticals Inc (CTXR) Ends at 0.37, Reflecting a -8.22 Downturn - The Dwinnex
There is no way Citius Pharmaceuticals Inc (CTXR) can keep these numbers up - SETE News
Citius Pharmaceuticals stock hits 52-week low at $0.39 By Investing.com - Investing.com Australia
Citius Pharmaceuticals stock hits 52-week low at $0.39 - Investing.com
Analyzing the Impact of Earnings Reports on Citius Pharmaceuticals Inc Inc. (CTXR) Price Performance - The InvestChronicle
Is Citius Pharmaceuticals Inc (CTXR) a threat to investors? - US Post News
Market Resilience: Citius Pharmaceuticals Inc (CTXR) Finishes Weak at 0.43, Down -2.60 - The Dwinnex
Citius Pharmaceuticals Inc (CTXR) Stock: A Year of Market Fluctuations - The InvestChronicle
Point72 DIFC Ltd Makes New $29,000 Investment in Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) - Defense World
Citius Pharmaceuticals Inc (CTXR) can make a big difference with a little luck - SETE News
Citius Pharmaceuticals stock hits 52-week low at $0.48 By Investing.com - Investing.com Canada
Citius Pharmaceuticals stock hits 52-week low at $0.48 - Investing.com
Post-Trade Analysis: Citius Pharmaceuticals Inc (CTXR) Climbs 0.95, Closing at 0.52 - The Dwinnex
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Sees Significant Decrease in Short Interest - MarketBeat
Citius Pharmaceuticals Inc’s results are impressive - US Post News
Citius Pharmaceuticals extends executive and warrant agreements - Investing.com India
Citius Pharmaceuticals extends executive and warrant agreements By Investing.com - Investing.com South Africa
BCA says a US recession remains the most likely outcome - Investing.com
Armistice Capital LLC Purchases New Position in Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) - MarketBeat
Financial Snapshot: Analyzing Citius Pharmaceuticals Inc (CTXR)’s Key Ratio Metrics - The Dwinnex
CTOR Stock Update: Citius Oncology Inc.’s Banking’s Market Struggles and Potential Opportunities - The InvestChronicle
Investor’s Delight: Cytek BioSciences Inc (CTKB) Closes Strong at 5.19, Up 1.96 - The Dwinnex
Check Out Citius Pharmaceuticals Inc (CTXR)’s Trade Data Rather Than the Analysts’ Views - SETE News
Cettire shares skyrocket - ShareCafe
CTXR’s price-to-book ratio: An indicator of the company’s performance - US Post News
Closing Strong: Citius Oncology Inc. (CTOR) Ends at 1.60, Down -4.19 from Last Close - The Dwinnex
XTX Topco Ltd Acquires 15,997 Shares of Catalent, Inc. (NYSE:CTLT) - Defense World
CitiusTech to pursue acquisitions, shifts hiring strategy on GenAI push - TechCircle
Citius Pharmaceuticals Inc (CTXR)’s Day in Review: Closing at 0.50, Down by -2.90 - The Dwinnex
The time has not yet come to remove your chips from the table: Citius Pharmaceuticals Inc (CTXR) - SETE News
Examining Citius Pharmaceuticals Inc (CTXR) stock is warranted - US Post News
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):